Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.61 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527192 | 0.99 | HTR1A (0.62) | HTR1ADRD2DRD3ADRA1AKDM4E | |
| Bromide SCHEMBL7532131 | 0.91 | HTR1A (0.67) | HTR1ADRD2DRD3ADRA1A | |
| SCHEMBL7528127 | 0.90 | HTR1A (0.68) | HTR1ADRD2DRD3ADRA1A | |
| Bromide SCHEMBL7528105 | 0.83 | LMNA (0.51) | HTR1ADRD2KDM4ESMN1; SMN2LMNA | |
| SCHEMBL7523988 | 0.82 | GRM2 (0.52) | HTR1ADRD2KDM4ESMN1; SMN2LMNA | |
| Bromide SCHEMBL7520978 | 0.80 | ALDH1A1 (0.56) | HTR1ADRD2DRD3ADRA1AKDM4E | |
| Bromide SCHEMBL7518122 | 0.80 | ADRA1A (0.55) | HTR1ADRD2DRD3ADRA1A | |
| SCHEMBL7528158 | 0.78 | ADRA1A (0.56) | HTR1ADRD2DRD3ADRA1A | |
| SCHEMBL7516307 | 0.78 | ALDH1A1 (0.57) | HTR1ADRD2DRD3ADRA1AKDM4E | |
| SCHEMBL8011275 | 0.76 | HTR1A (1.00) | HTR1ADRD2DRD3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | claimed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | claimed |
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | HTR1A 16/4885ADRA1A 74/4885DRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.